ω-Agatoxin IVA TFA: Precision Cav2.1 Calcium Channel Blocker for Synaptic Transmission Research

Executive Summary: ω-Agatoxin IVA TFA is a peptide toxin derived from funnel-web spider venom and supplied by APExBIO as a trifluoroacetate salt form for research use (APExBIO). It is a highly specific blocker of P/Q-type (Cav2.1) voltage-gated calcium channels, with IC50 values between 1–2 nM for P-type variants lacking the NP motif and up to 270.5 nM for Q-type variants containing the NP motif (Singh et al., 2023). The compound exhibits weak partial inhibition of N-type channels at 1 μM and does not affect L- or T-type channels. In vitro, typical application concentrations range from 100 nM to 1 μM for neuronal calcium current recordings and synaptic transmission studies. In vivo, it has validated anticonvulsant, neuroprotective, and anti-apoptotic effects in epilepsy models, without impairing motor coordination.

Biological Rationale

P/Q-type voltage-gated calcium channels (Cav2.1) are essential mediators of neurotransmitter release in central neurons, controlling synaptic efficacy and plasticity (Singh et al., 2023). Genetic or pharmacological disruption of Cav2.1 impairs evoked GABA and glutamate release, alters excitation/inhibition balance, and is linked to epilepsy and neurodevelopmental disorders. Highly selective Cav2.1 inhibitors, such as ω-Agatoxin IVA TFA, enable precise mechanistic dissection of these processes. Unlike broad-spectrum calcium channel blockers, ω-Agatoxin IVA TFA allows researchers to isolate P/Q-type channel function, facilitating targeted investigations in synaptic physiology, pathogenesis, and neuroprotection. The compound is also a key tool for validating disease models where Cav2.1 dysfunction is implicated.

Mechanism of Action of ω-Agatoxin IVA TFA

ω-Agatoxin IVA TFA operates by binding to the α1A subunit of Cav2.1 channels, causing a conformational change that blocks calcium influx through P/Q-type channels (Singh et al., 2023). The inhibition is highly potent and subtype-selective: nanomolar concentrations (1–2 nM) are sufficient to block P-type Cav2.1 variants lacking the NP motif, while higher concentrations (up to 270.5 nM) are required for Q-type variants containing the motif. At 1 μM, only weak partial inhibition of N-type channels is observed, with no effects on L-type or T-type channels. By preventing calcium entry, ω-Agatoxin IVA TFA suppresses evoked neurotransmitter release (glutamate and GABA), modulates synaptic plasticity, and regulates neuronal excitability. The compound has also been shown to mediate nicotinic activation regulation of cardiac vagal neurons, linking it to autonomic function.

Evidence & Benchmarks

• ω-Agatoxin IVA TFA blocks P/Q-type (Cav2.1) calcium channels with IC50 values of 1–2 nM (P-type, NP motif–) and 270.5 nM (Q-type, NP motif+) in mammalian neurons (Singh et al., 2023).
• At 1 μM, the compound causes weak partial inhibition of N-type calcium channels, but does not affect L-type or T-type channels (Singh et al., 2023).
• In vitro, application concentrations of 100 nM to 1 μM are standard for neuronal calcium current and synaptic transmission assays (APExBIO).
• Intracerebroventricular doses of 0.01–1 nM and intraperitoneal doses of 0.1–0.5 nM are effective in rodent epilepsy models, with anticonvulsant and neuroprotective outcomes (APExBIO).
• Therapeutic effects include prolongation of seizure latency, inhibition of epilepsy progression, reduced apoptosis (decreased cleaved caspase-3), and increased BDNF expression, all without affecting motor function (Singh et al., 2023).
• GABA release from parvalbumin interneurons in mouse cortical slices is insensitive to ω-Agatoxin IVA after Grin1 (NMDAR subunit) deletion, confirming the necessity of Cav2.1 recruitment for synchronous release (Singh et al., 2023).

For an in-depth mechanistic perspective on Cav2.1 inhibition and translation to epilepsy models, see "ω-Agatoxin IVA TFA: Redefining Precision in Cav2.1 Channel Research". This article extends that analysis by focusing on validated in vivo and in vitro dosing benchmarks and the neuroprotective profile in apoptosis inhibition.

Applications, Limits & Misconceptions

ω-Agatoxin IVA TFA is widely used in:

• Neuronal calcium current recording and synaptic transmission research.
• Epilepsy animal models for anticonvulsant and neuroprotection studies.
• Mechanistic studies of Cav2.1-dependent neurotransmitter release and synaptic plasticity.
• Assays targeting apoptotic pathways, including caspase-3 inhibition and BDNF induction.
• Electrophysiology workflows in brain slice or primary neuronal cultures.

For practical assay design, see "Optimizing Neuronal Assays with ω-Agatoxin IVA TFA (SKU C8722)", which this article updates with new quantitative and selectivity data.

Common Pitfalls or Misconceptions

• Not a pan-calcium channel blocker: ω-Agatoxin IVA TFA does not block L-type or T-type channels, even at high micromolar concentrations; it is selective for Cav2.1.
• Incomplete block of N-type channels: Only weak partial inhibition of N-type (Cav2.2) channels occurs at 1 μM; it cannot replace N-type–selective antagonists.
• Not suitable for long-term stock solutions: The compound is unstable and should be used promptly after preparation; store at –20°C under nitrogen, protected from moisture and light.
• Does not rescue Cav2.1-independent synaptic release: GABA release following NMDAR (Grin1) deletion is insensitive to ω-Agatoxin IVA TFA, indicating channel recruitment is required (Singh et al., 2023).
• No effect on intrinsic neuronal excitability: The compound does not alter K+ channel–mediated excitability or compensate for genetic loss of Cav2.1 function.

For a structural and mechanistic complement, see "ω-Agatoxin IVA TFA: Mechanistic Insights and Advanced Applications", which this article clarifies by highlighting validated dosing and in vivo effects.

Workflow Integration & Parameters

ω-Agatoxin IVA TFA (SKU C8722) is supplied as a trifluoroacetate salt with a molecular weight of 5316.27 Da. Researchers should store the lyophilized product at –20°C under nitrogen, shielded from moisture and light. Reconstitute freshly before use; long-term storage of solutions is not recommended. For in vitro neuronal assays, recommended working concentrations are 100 nM to 1 μM, typically in calcium current or synaptic transmission recording buffers. For in vivo acute epilepsy models, intracerebroventricular doses of 0.01–1 nM are effective; for kindling models, intraperitoneal doses of 0.1–0.5 nM have been validated. The compound is compatible with patch-clamp electrophysiology, calcium imaging, and apoptosis assays. For workflow reproducibility and detailed protocols, see the ω-Agatoxin IVA TFA product page and recent best-practices articles.

Conclusion & Outlook

ω-Agatoxin IVA TFA, as formulated by APExBIO, is a validated, highly selective Cav2.1 inhibitor for use in both basic and translational neuroscience. Its nanomolar potency, channel specificity, and established neuroprotective effects underpin its value in synaptic transmission, epilepsy, and neurodegeneration research. Ongoing advances in Cav2.1 structural biology and disease modeling will further expand its applications. Future studies may illuminate new therapeutic avenues, particularly in disorders characterized by Cav2.1 dysfunction or aberrant synaptic plasticity.